1. Home
  2. PLUS vs SUPN Comparison

PLUS vs SUPN Comparison

Compare PLUS & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ePlus inc.

PLUS

ePlus inc.

HOLD

Current Price

$91.17

Market Cap

2.3B

Sector

Technology

ML Signal

HOLD

Logo Supernus Pharmaceuticals Inc.

SUPN

Supernus Pharmaceuticals Inc.

HOLD

Current Price

$47.08

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLUS
SUPN
Founded
1990
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.8B
IPO Year
1996
2010

Fundamental Metrics

Financial Performance
Metric
PLUS
SUPN
Price
$91.17
$47.08
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$61.60
AVG Volume (30 Days)
241.1K
950.3K
Earning Date
05-21-2026
05-05-2026
Dividend Yield
1.20%
N/A
EPS Growth
24.20
N/A
EPS
5.03
N/A
Revenue
$2,442,549,000.00
$392,755,000.00
Revenue This Year
$19.83
$22.70
Revenue Next Year
$4.36
$19.14
P/E Ratio
$17.82
N/A
Revenue Growth
18.07
N/A
52 Week Low
$62.11
$32.21
52 Week High
$93.98
$59.68

Technical Indicators

Market Signals
Indicator
PLUS
SUPN
Relative Strength Index (RSI) 67.08 51.49
Support Level $86.41 $43.43
Resistance Level $93.17 $52.36
Average True Range (ATR) 3.07 1.62
MACD 1.09 0.34
Stochastic Oscillator 90.06 43.31

Price Performance

Historical Comparison
PLUS
SUPN

About PLUS ePlus inc.

ePlus Inc is a provider of technology solutions across the IT spectrum, spanning security, cloud, data center, networking, collaboration, AI, service provider, and critical infrastructure, and emerging solutions, to domestic and foreign organizations across all industry segments. Its solutions leverage a broad range of professional, consultative, and managed services across the technology spectrum. The company possesses top-level engineering certifications with a broad range of IT technologies that enable the company to offer multi-vendor IT solutions that are optimized for each of its customers' specific requirements. It also offers a wide portfolio of technology and other capital asset financing solutions to customers across commercial and government enterprises, designing programs.

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.

Share on Social Networks: